Ifp Advisors, Inc Eagle Pharmaceuticals, Inc. Transaction History

Ifp Advisors, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	BUY	$26.42 - $47.12 $52 - $94	2 Added 16.67%	14 $3,000
Q2 2022 Sep 06, 2022	BUY	$41.26 - $51.35 $495 - $616	12 New	12 $3,000
Q2 2022 Aug 12, 2022	SELL	$41.26 - $51.35 $495 - $616	-12 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$44.58 - $52.6 $534 - $631	12 New	12 $0
Q3 2021 Oct 06, 2021	SELL	$43.79 - $55.78 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$36.86 - $44.5 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$40.32 - $50.97 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	BUY	$41.72 - $51.34 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$37.02 - $51.28 $0 - $0	0 New	0 $0

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.